Welcome


Director, Professor
Dr. Jiandong JIANG

Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College, founded in 1958, is currently accommodating more than 300 research scientists and technicians, and among them more than 95 are holding full and associate professorships, two were elected Academician of Chinese Academy of Sciences and an Academician of Chinese Academy of Engineering. 57 of our staff members have received “special government allowance”, which is an official acknowledge-ment for those who made substantial contribution to science and technology. We also have  ten professors winning the title “outstanding contributor”, two honored by the central government of China and eight by Chinese Ministry of Public Health. 5 belong to “New Century Bai-Qian-Wan Talented personnel project.” 4 earned “Outstanding Young Scholar” support from Chinese  Natural Sciences Foundation,  3 are “Yangtze River Scholar”

 professors, and another 3 were entitled “Peking Union Medical College Scholars”. In the recent years, the institute has proudly employed over 30 talented and dedicated scientists.

The fundamental task of IMM centers on research and discovery of innovative drugs useful in treating or preventing human diseases. To fulfill this goal, creative multidiscipline researches based on Chinese herbal medicine and natural product research, along with adoption of modern medical and pharmaceutical theories and technologies, are highly encouraged. Currently, ongoing projects in this institute covers a number of important research areas, including cancer, cardio and cerebral vascular diseases, psycho and neuro-disorders, aging associated regressive diseases, hepatitis, inflammatory and immuno disorders and diabetes. 

IMM comprises of seven departments: Department of Synthetic Medicinal Chemistry, Department of Natural Medicinal Chemistry, Department of Pharmacology, Department of Drug Analysis, Department of Biosynthesis, Department 1 of Drug Development Research and Department 2 of Drug Development Research. Being a full-range-disciplined research institution, IMM’s capacity in drug research and development is well recognized nationalwide. Its programs in natural product research, computer aided drug design, combinatorial chemistry, molecular pharmacology and high-through-put screening, enjoys great prestige in China.  

In addition, the institute also hosts a number of government-sponsored special research centers, including the National Research Center for Analysis of Drugs and Metabolites, the National Engineering Research Center for Development of New Drugs, the National Center for Pharmaceutical Screening, Pharmacodynamics Platform (Ministry of Science & Technology), New Drug Safety Evaluation Center [the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)], the Key laboratory of Biosynthesis of Natural Products (Ministry of Health), and the Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine (Ministry of Education). In 2011, it has been approved for the establishment of the State Key Laboratory of Bioactive Substance and Function of Natural Medicines, and three Beijing City Key Laboratories, which is Beijing City Key Laboratory of Active Substances discovery and Drugability Evaluation, Beijing City Key Laboratory for Drug Target Identification and Drug Screening, as well as Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations. Since 2008, several major national platform programs funded by central government have been established in IMM to further enhance the drug R&D capacity, and it has substantially improved our research quality.  

There are also several IMM-owned enterprises manufacturing drug products and providing technical services. They are Beijing Union Pharmaceutical Factory, Beijing Union Second Pharmaceutical Factory, Beijing LianXin Pharmaceutic Co., Ltd., Beijing Union-Genius Pharmaceutical Technology Co., Ltd., Beijing Collab Pharma Co., Ltd. In general, through combination of basic research and R&D application, IMM serves the nation and patients with new drugs as well as industrial drug production. 

Since the time of its establishment, scientists in this institute have accomplished research for more than 100 marketed drugs and 129 new drug certificates, including 19 Class I novel drugs. 261 government and society awards or prizes were granted to the contributors for their research efforts in drug R&D. Since the inception of the new research funding system in China in 1986, over 900 IMM grant applications have been approved in total. These studies have resulted in more than 6000 publications, 350 monographs, as well as 500 domestic and international patent applications. 

IMM is also a national core base for the training of high-quality pharmaceutical professionals. Over 300 graduate students are currently studying on the campus, and up to 2011 541 PhD and 538 MS students have graduated. Furthermore, the IMM’s Pharmaceutical Science discipline was named to be the “National University Medical Key Discipline” by the Ministry of Education, with post-doctoral fellow training certification. 

IMM has the capacity to operate the institute with the market-driven economy, which accelerates the commercialization of the basic research, and increases the market value of the business entities that are owned by or are affiliated to the Institute. Currently the main products discovered and developed by IMM researchers include Bicyclol Tablets, Paclitaxel Injection, Felodipine Tablets, Bifendate Pilules and Polysaccharidum of G. Lucidum Karst Injection, some of which have been launched into international markets in Europe, Asia and North Africa. 

IMM has established extensive partnerships and collaboration with pharmaceutical companies, universities and research institutes in more than 30 countries, including Japan, the United States, Germany and France. IMM also hosts the editorial offices of four scientific journals: Acta Pharmaceutica Sinica, Chinese Chemical Letters, Journal of Asian Natural Products Research and Acta Pharmaceutica Sinica B.

In the future, IMM will work hard in the spirit of "Devotion, Innovation, Reality and Cooperation" to launch more quality drugs, and to make contribution for human health.

Address: 1 Xian Nong Tan Street, Beijing 100050 China
Tel: +86-10-63037394  Fax:+86-10-63017757